Corpus Intelligence IC Memo — PAM SPEC HOSPITAL OF PITTSBURGH 2026-04-26 15:53 UTC
IC Memo — PAM SPEC HOSPITAL OF PITTSBURGH
Investment Committee Memorandum | PA | 63 beds | Grade D | EBITDA uplift $894K
🛡️ Public data only — no PHI permitted on this instance.
Investment Committee Memorandum

PAM SPEC HOSPITAL OF PITTSBURGH

CCN 392028 | ALLEGHENY, PA | 63 beds | April 26, 2026
EBITDA BridgeData Room
D
Investability

1. Target Overview & Investment Thesis

PAM SPEC HOSPITAL OF PITTSBURGH is a 63-bed community hospital in ALLEGHENY, PA with $12.1M in net patient revenue and a -10.5% operating margin. The hospital serves a payer mix of 49.8% Medicare, 0.0% Medicaid, and 50.2% commercial.

Thesis: Turnaround. Our ML models identify $894K in annual EBITDA improvement potential from RCM optimization across 5 levers, lifting margin from -10.5% to -3.1% (+739bps).

Net Revenue HCRIS$12.1M
Current EBITDA COMPUTED$-1.3M
Operating Margin COMPUTED-10.5%
Occupancy HCRIS28.6%
Revenue / Bed COMPUTED$192K
Net-to-Gross HCRIS31.8%
Distress Probability MLnan%

2. Market Context & Competitive Position

225
PA Hospitals
-4.4%
State Median Margin
88
Comparable Hospitals

PA has 225 Medicare-certified hospitals with a median operating margin of -4.4%. The target's margin of -10.5% places it below the state median. Among 88 size-comparable peers (32-126 beds), the median margin is 1.7%. The target's below-peer margin suggests operational improvement opportunity.

3. RCM Performance Analysis — Comparable Hospitals

Comps selected by bed count (32-126), prioritizing same-state peers. 88 hospitals in the comp set.

HospitalStateBedsRevenueMargin
PAM SPEC HOSPITAL OF PITTSBURG (Target)PA63$12.1M-10.5%
THE GETTYSBURG HOSPITALPA76$341.8M18.4%
EPHRATA COMMUNITY HOSPITALPA115$291.8M3.8%
AMERICAN ONCOLOGIC HOSPIALPA100$229.8M-11.1%
EVANGELICAL COMMUNITY HOSPITALPA119$223.6M5.1%
ST. LUKES HOSPITAL - MONROE CAPA98$221.8M7.8%
GEISINGER LEWISTOWN HOSPITALPA107$210.8M11.2%
UPMC HANOVERPA73$200.8M18.2%
MEMORIAL HOSPITALPA80$184.5M13.1%

4. Predicted Improvement Opportunities

Improvement targets set at P75 of comparable peers with 60% gap closure assumption. Coefficients calibrated to published research bands. Total EBITDA uplift: $894K (739bps margin improvement).

LeverCurrentTargetEBITDA ImpactMarginRamp
Net Collection Rate93.5%97.0%$254K+210bp18mo
Cost to Collect4.5%2.5%$242K+200bp12mo
Denial Rate Reduction12.0%6.5%$241K+199bp12mo
A/R Days Reduction5200.0%3800.0%$147K+122bp9mo
Clean Claim Rate88.0%96.0%$10K+8bp6mo

5. EBITDA Bridge

Net Collection Rate
$254K
Cost to Collect
$242K
Denial Rate Reduction
$241K
A/R Days Reduction
$147K
Clean Claim Rate
$10K
Total EBITDA Uplift$894K
Current EBITDA$-1.3M
+ RCM Uplift+$894K
Pro Forma EBITDA$-374K
Current Margin-10.5%
Pro Forma Margin-3.1%
WC Released (1x)$464K

6. Returns Analysis — Scenario Matrix

5-year hold, 5.5x leverage, 3% organic growth, 10%/yr debt paydown. Base case uses 100% of predicted RCM uplift. Bull case: 130% uplift at lower entry. Bear case: 50% uplift at higher entry.

ScenarioEntryExitEquity InEquity OutMOICIRR
Base Case10.0x10.0x$-2.0M$579K0.00x-100.0%
Base (11x exit)10.0x11.0x$-2.0M$3K0.00x-100.0%
Bull Case9.0x11.0x$-1.8M$2.3M0.00x-100.0%
Bull (12x exit)9.0x12.0x$-1.8M$2.0M0.00x-100.0%
Bear Case11.0x10.0x$-2.1M$-3.3M0.00x-100.0%
Bear (11x exit)11.0x11.0x$-2.1M$-4.3M0.00x-100.0%

7. Key Risks & Mitigants

SeverityRisk FactorMitigant
HighNegative operating marginRCM uplift bridge shows clear path to profitability; working capital release provides near-term cash cushion
MediumLow occupancyAt 28.6%, fixed costs are spread over fewer patient days. Mitigant: volume growth is an additional upside lever not modeled in base case

8. Data Sources & Methodology Appendix

Data Sources

  • CMS HCRIS Cost Reports (Medicare-certified hospitals)
  • CMS Medicare Utilization (DRG-level volumes)
  • CMS Chronic Conditions (county-level disease prevalence)
  • HCRIS multi-year trend data (financial time series)

Comparable Selection

  • 88 hospitals with 32-126 beds
  • Same-state prioritization (n=89)
  • Comp margins: P25=-18.3% / P50=1.7% / P75=9.5%

Bridge Methodology

  • Targets: P75 of comparable peers (60% gap closure)
  • Denial: avoidable share = 35% of delta × NPR
  • AR: bad debt coefficient = $0.65 per day per $1K NPR
  • NCR: 60% coefficient on collection rate improvement
  • CDI: 0.75% of Medicare revenue per 0.01 CMI point

Returns Assumptions

  • Leverage: 5.5x entry (84.6% debt / 15.4% equity)
  • Organic growth: 3% annual EBITDA growth
  • Debt paydown: 10% of principal per year
  • Hold period: 5 years

Generated by SeekingChartis on April 26, 2026. All predictions use public data only. Confidence intervals calibrated via split conformal prediction (90% coverage target). This memo is for informational purposes and does not constitute investment advice.